GENTAUR Europe BVBA
Genprice Inc, Logistics
Serbia, 
Macedonia, 
Montenegro, 
Croatia: 
GENTAUR Romania
GENTAUR Greece 
U.S. researchers said they have achieved very good results in clinical testing of an experimental vaccine against malaria, world agencies reported.
The disease caused by the parasite each year causing 600,000 deaths, mostly among children in Africa. The vaccine is derived from a number of attenuated parasites Plasmodium fa, an infection spread by female mosquitoes of the genus Anofelesi. It is one hundred percent protection achieved in six out of nine adult volunteers who received the highest dose of it. In these primary tests involved 40 people aged between 20 and 44 years.
"Although we are in the early stages of the development of the vaccine, we are confident that our vaccine will help us to fight malaria," said Stephen Hoffman, executive director of the laboratory "Sanary" in which are held
research. They are funded by the U.S. National Institute of Allergy and Infectious Diseases and other organizations from the U.S., Europe and Africa.
Scientists 30 years trying to develop antimalarial vaccine. But only now have a very safe immunization tool that is injected and can save millions of lives, "said Hoffman.
Although extremely hopeful results, some experts are still skeptical of the small number of subjects on which it was tested the new vaccine.
For this reason, the scientific team will undertake additional clinical trials in Germany, the U.S. and Africa. Those skilled will test and a different frequency of vaccination in order to achieve one hundred percent protection against at least 5 doses of the novel vaccine.
So far, the way to extract parasites from the salivary glands of mosquitoes is quite slow and requires the efforts of 12 to 15 professionals who manage to dissect around 150 insects per hour. Another difficulty is that the vaccine must be stored in liquid nitrogen. Laboratory "Sanary" already collaborates with Harvard University to automate the process.
